@article{Hager_K-2022_100858,
title = {Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine},
author = {Hager, K. and Pérez Marc, G. and Gobeil, P. and Diaz, R. and Heizer, G. and Llapur, C. and Makarkov, A. and Vasconcellos, E. and Pillet, S. and Riera, F. and Saxena, P. and Geller Wolff, P. and Bhutada, K. and Wallace, G. and Aazami, H. and Jones, C. and Polack, F. and Ferrara, L. and Atkins, J. and Boulay, I. and Dhaliwall, J. and Charland, N. and Couture, M. and Jiang-Wright, J. and Landry, N. and Lapointe, S. and Lorin, A. and Mahmood, A. and Moulton, L. and Pahmer, E. and Parent, J. and Séguin, A. and Tran, L. and Breuer, T. and Ceregido, M. and Koutsoukos, M. and Roman, F. and Namba, J. and D'Aoust, M. and Trepanier, S. and Kimura, Y. and Ward, B. and Team, C.},
month = {may},
year = {2022},
abstract = {Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine.},
pages = {2084-2096},
volume = {386},
journal = {New England Journal of Medicine},
publisher = {Massachusetts Medical Society},
url = {https://doi.org/10.1056/NEJMoa2201300},
}
